Compare

Arrowhead Pharmaceuticals, Inc. vs ANI Pharmaceuticals Inc vs Corcept Therapeutics Inc vs Emergent BioSolutions Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Arrowhead Pharmaceuticals, Inc. ARWR	ANI Pharmaceuticals Inc ANIP	Corcept Therapeutics Inc CORT	Emergent BioSolutions Inc. EBS
Year ended	2025-09-30	2025-12-31	2025-12-31	2025-12-31
Revenue	$829.45M	$883.37M	$761.41M	$742.90M
Revenue growth (YoY)	n/m	+43.8%	+12.8%	-28.8%
Gross margin	n/a	n/a	n/a	56.1% (computed)
Operating margin	11.9%	12.6%	5.9%	13.5%
Net margin	3.6%	8.9%	13.1%	7.1%
Net income	$30.11M	$78.34M	$99.65M	$52.60M
EPS (Diluted)	-$0.01	$3.32	$0.82	$0.93
Operating cash flow	$179.55M	$185.22M	$142.00M	$170.60M
Free cash flow	$156.89M	$171.39M	$141.78M	$156.80M
Cash & equivalents	n/a	$285.58M	$120.50M	$205.40M
Total assets	$1.39B	$1.44B	$836.65M	$1.32B
Total liabilities	n/a	$899.65M	$188.85M	$796.00M
Shareholders' equity	$503.42M	$540.72M	$647.80M	$522.60M
Return on year-end equity	6.0%	14.5%	15.4%	10.1%
Shares outstanding	135.70M	22.49M	105.97M	52.10M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Arrowhead Pharmaceuticals, Inc.	ANI Pharmaceuticals Inc	Corcept Therapeutics Inc	Emergent BioSolutions Inc.
Latest	$829.45M Ended 2025-09-30	$883.37M Ended 2025-12-31	$761.41M Ended 2025-12-31	$742.90M Ended 2025-12-31
1 year earlier	$3.55M Ended 2024-09-30	$614.38M Ended 2024-12-31	$675.04M Ended 2024-12-31	$1.04B Ended 2024-12-31
2 years earlier	$240.74M Ended 2023-09-30	$486.82M Ended 2023-12-31	$482.38M Ended 2023-12-31	$1.05B Ended 2023-12-31
3 years earlier	$243.23M Ended 2022-09-30	$316.38M Ended 2022-12-31	$401.86M Ended 2022-12-31	$1.12B Ended 2022-12-31
4 years earlier	$138.29M Ended 2021-09-30	$216.14M Ended 2021-12-31	$365.98M Ended 2021-12-31	$1.77B Ended 2021-12-31